Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan

D. Pascual-Figal, R. Wachter, M. Senni, J. Belohlavek, A. Noè, D. Carr, D. Butylin,

. 2018 ; 5 (2) : 327-336. [pub] 20171214

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19001036

AIMS: The prognosis after hospitalization for acute decompensated heart failure (ADHF) remains poor, especially <30 days post-discharge. Evidence-based medications with prognostic impact administered at discharge improve survival and hospital readmission, but robust studies comparing pre-discharge with post-discharge initiation are rare. The PARADIGM-HF trial established sacubitril/valsartan as a new evidence-based therapy in patients with heart failure (HF) and reduced left ventricular ejection fraction (<40%) (rEF). In common with other landmark studies, it enrolled patients who were ambulatory at the time of inclusion. In addition, there is also still limited knowledge of initiation and up-titration of sacubitril/valsartan in ACEi/ARB- naïve patients and in de novo HF with rEF patients. METHODS AND RESULTS: TRANSITION is a multicentre, open-label study in which ~1000 adults hospitalized for ADHF with rEF are randomized to start sacubitril/valsartan in a pre-discharge arm (initiated ≥24 h after haemodynamic stabilization) or a post-discharge arm (initiated within Days 1-14 after discharge). The protocol allows investigators to select the appropriate starting dose and dose adjustments according to clinical circumstances. Over a 10 week treatment period, the primary and secondary objectives assess the feasibility and safety of starting sacubitril/valsartan in-hospital, early after haemodynamic stabilization. Exploratory objectives also include assessment of HF signs and symptoms, readmissions, N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T levels, and health resource utilization parameters. CONCLUSIONS: TRANSITION will provide new evidence about initiating sacubitril/valsartan following hospitalization for ADHF, occurring either as de novo ADHF or as deterioration of chronic HF, and in patients with or without prior ACEI/ARB therapy. The results of TRANSITION will thus be highly relevant to the management of patients hospitalized for ADHF with rEF.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001036
003      
CZ-PrNML
005      
20190124122639.0
007      
ta
008      
190107s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ehf2.12246 $2 doi
035    __
$a (PubMed)29239515
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pascual-Figal, Domingo $u Heart Failure and Heart Transplantation Unit, Cardiology Department, Virgen de la Arrixaca University Hospital, Universidad de Murcia, Ctra. Madrid-Cartagena s/n, 30120, Murcia, Spain.
245    10
$a Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan / $c D. Pascual-Figal, R. Wachter, M. Senni, J. Belohlavek, A. Noè, D. Carr, D. Butylin,
520    9_
$a AIMS: The prognosis after hospitalization for acute decompensated heart failure (ADHF) remains poor, especially <30 days post-discharge. Evidence-based medications with prognostic impact administered at discharge improve survival and hospital readmission, but robust studies comparing pre-discharge with post-discharge initiation are rare. The PARADIGM-HF trial established sacubitril/valsartan as a new evidence-based therapy in patients with heart failure (HF) and reduced left ventricular ejection fraction (<40%) (rEF). In common with other landmark studies, it enrolled patients who were ambulatory at the time of inclusion. In addition, there is also still limited knowledge of initiation and up-titration of sacubitril/valsartan in ACEi/ARB- naïve patients and in de novo HF with rEF patients. METHODS AND RESULTS: TRANSITION is a multicentre, open-label study in which ~1000 adults hospitalized for ADHF with rEF are randomized to start sacubitril/valsartan in a pre-discharge arm (initiated ≥24 h after haemodynamic stabilization) or a post-discharge arm (initiated within Days 1-14 after discharge). The protocol allows investigators to select the appropriate starting dose and dose adjustments according to clinical circumstances. Over a 10 week treatment period, the primary and secondary objectives assess the feasibility and safety of starting sacubitril/valsartan in-hospital, early after haemodynamic stabilization. Exploratory objectives also include assessment of HF signs and symptoms, readmissions, N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T levels, and health resource utilization parameters. CONCLUSIONS: TRANSITION will provide new evidence about initiating sacubitril/valsartan following hospitalization for ADHF, occurring either as de novo ADHF or as deterioration of chronic HF, and in patients with or without prior ACEI/ARB therapy. The results of TRANSITION will thus be highly relevant to the management of patients hospitalized for ADHF with rEF.
650    _2
$a akutní nemoc $7 D000208
650    _2
$a senioři $7 D000368
650    _2
$a aminobutyráty $x aplikace a dávkování $7 D000613
650    _2
$a antagonisté receptorů pro angiotenzin $x aplikace a dávkování $7 D057911
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a propuštění pacienta $7 D010351
650    12
$a znovupřijetí pacienta $7 D010359
650    _2
$a prognóza $7 D011379
650    _2
$a tepový objem $x účinky léků $x fyziologie $7 D013318
650    _2
$a tetrazoly $x aplikace a dávkování $7 D013777
650    _2
$a výsledek terapie $7 D016896
650    _2
$a funkce levé komory srdeční $x účinky léků $x fyziologie $7 D016277
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Wachter, Rolf $u Clinic and Policlinic for Cardiology, University Hospital Leipzig, Germany.
700    1_
$a Senni, Michele $u Cardiology Division, Cardiovascular Department, Hospital Papa Giovanni XXIII-Bergamo, Bergamo, Italy.
700    1_
$a Belohlavek, Jan $u Complex Cardiovascular Centre, General Teaching Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Noè, Adele $u Novartis Pharma AG, Basel, Switzerland.
700    1_
$a Carr, David $u Novartis Pharma AG, Basel, Switzerland.
700    1_
$a Butylin, Dmytro $u Novartis Pharma AG, Basel, Switzerland.
773    0_
$w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 5, č. 2 (2018), s. 327-336
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29239515 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190124122902 $b ABA008
999    __
$a ok $b bmc $g 1364985 $s 1039159
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 5 $c 2 $d 327-336 $e 20171214 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Archiving options